InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,667.20
(
0.64%
)
US TECH 100
19,826.80
(
-0.10%
)
Dow Jones
40,954.48
(
1.85%
)
Brent Oil
83.32
(
-1.22%
)
Bitcoin
65,194.45
(
0.42%
)
Post# of 252612
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120057
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: justrpaul post# 197248

Monday, 11/16/2015 11:40:42 AM

Monday, November 16, 2015 11:40:42 AM

Post# of 252612

MRK— why would they even advance to further testing?

MRK’s 3-DAA data are tepid, but not awful; from a business standpoint, I don’t think it’s wrong for MRK to advance the 3-DAA regimen to phase-2b. However, I do question whether this regimen is potent enough to support an 8-week duration for all genotypes.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up